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A randomized trial was carried out com-
paring cyclosporin A (CsA) and short-
term methotrexate (MTX) versus CsA
alone for graft versus host disease
(GVHD) prophylaxis in patients with se-
vere aplastic anemia (SAA) undergoing
allogeneic bone marrow transplantation
(BMT) from a compatible sibling. Seventy-
one patients (median age, 19 years; range,
4-46 years) were randomized to receive
either CsA and MTX or CsA alone for the
first 3 weeks after BMT. Subsequently,
both groups received CsA orally, with
gradual drug reduction until discontinua-
tion 8 to 12 months after BMT. Patients
randomized in both arms had comparable
characteristics and received the same
preparative regimen (ie, cyclophospha-
mide 200 mg/kg over 4 days). The median
time for neutrophil engraftment was 17
days (range, 11-31 days) and 12 days
(range, 4-45 days) for patients in the CsA/
MTX group and the CsA alone group,
respectively (P 5 .01). No significant dif-
ference was observed in the probability
of either grade 2, grade 3, or grade 4 acute
GVHD or chronic GVHD developing in the
2 groups. The Kaplan-Meier estimates of
1-year transplantation-related mortality
rates for patients given either CsA/MTX or
CsA alone were 3% and 15%, respectively
(P 5 .07). With a median follow-up of 48
months from BMT, the 5-year survival prob-
ability is 94% for patients in the CsA/MTX
group and 78% for those in the CsA alone
group (P 5 .05). These data indicate that the
use of CsA with MTX is associated with
improved survival in patients with SAA who
receive transplants from compatible
siblings. (Blood. 2000;96:1690-1697)
© 2000 by The American Society of Hematology
Introduction
Several studies have documented that many patients with acquired
severe aplastic anemia (SAA) can be cured by allogeneic bone
marrow transplantation (BMT) from a human leukocyte antigen
(HLA)-identical sibling.1-5 Results have constantly improved over
time,6 and several patient- and disease-related variables may have
contributed to increase the survival rate of patients with SAA who
undergo BMT from compatible siblings.
Earlier transplantation,6 more effective supportive care, and the
addition of antithymocyte globulin (ATG) to cyclophosphamide in
the preparative regimen7 have favorably influenced the outcome for
patients with SAA who undergo transplantation. In particular, the
introduction of cyclosporin A (CsA) instead of methotrexate
(MTX) as graft versus host disease (GVHD) prophylaxis has been
reported in some studies to decrease transplant-related mortality
(TRM)6,8 and the risk for graft failure.4,8 Previously published
studies have documented that patients with SAA given CsA and
short-term MTX for GVHD prevention enjoyed better results in
comparison with those treated with MTX alone.6,7,9-11 However,
though several studies have compared the use of CsA versus CsA
plus short-term MTX as GVHD prophylaxis in patients with
leukemia,12-14 no prospective, controlled study has specifically
addressed this issue in patients with SAA receiving BMT from
compatible relatives.
On this basis, we evaluated—in a multicenter, randomized,
prospective clinical trial—whether the use of CsA and short-term
MTX for GVHD prevention could be associated with better
survival than CsA alone in patients with acquired SAA who
received allogeneic BMT from HLA-compatible siblings.
Patients and methods
Study design
The major endpoint of the study was to determine whether the combination
of CsA and MTX could improve overall survival rates compared with CsA
alone. Secondary endpoints were the occurrence of acute and chronic
GVHD and the kinetics of neutrophil recovery in both randomization arms.
Eligibility criteria for patients to be enrolled in the study were age from
2 to 50 years, diagnosis of acquired SAA according to the criteria published
by Camitta et al,15 availability of an HLA genotypically identical sibling,
and written informed consent from the patient or the patient’s parents.
To calculate the number of patients to be enrolled into this study, a
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2-sided sample size evaluation method based on the log-rank test was used.
To obtain a study significance level of 0.05 and a study power of 0.80 and
supposing an estimated overall survival probability at 36 months of 0.90 for
the first arm and 0.65 for the second arm of the study, 35 patients per arm
with an accrual time of 5 years and an overall study duration of 7 years were
required. To monitor the results of the trial, interim analysis was performed
3 years after the beginning of the study and, subsequently, every year. It was
decided that patient enrollment should be closed when the difference in
overall survival between the 2 arms reached P 5 .05.
Randomization was centralized at the Department of Hematology,
Ospedale San Martino, Genoa, Italy, by one of the investigators (B.B.) not
involved in the clinical management of the patients, and it was performed
using a 1:1 allocation ratio. Patients were stratified according to the center
where they underwent transplantation. Analysis was based on the intention-
to-treat principle. Institutions participating in the study were not blind to the
GVHD prophylaxis used. Grading of acute and chronic GVHD was
performed by a single observer, who was expected to be blind to the
randomization arm.
Treatment protocol
The pretransplant conditioning regimen consisted of cyclophosphamide (50
mg/kg recipient body weight intravenously on each of 4 successive days).
All patients received unmanipulated marrow within 36 hours of the last
dose of cyclophosphamide.
The day of transplantation was designated as day 0. Between days 27
and 23, patients were randomized to receive CsA alone at a dosage of 3
mg/kg per day (CsA group) or CsA at the same dosage together with
short-term MTX (8 mg/m2 on days 1, 3, 6, and 11; CsA/MTX group)
starting from day 21. Subsequently, when patients were able to tolerate oral
intake, they were given CsA at a dosage of 6 mg/kg per day in 2 divided
doses, with gradual reduction until it could be discontinued, in the absence
of chronic GVHD, 6 to 12 months after BMT. No other agent was used for
GVHD prophylaxis. Compared with the original schedule described by
Storb et al,12 the reduced dosage of MTX was chosen on the hypothesis that
a lower drug dose could shorten the period of neutropenia and diminish
mucosal breakdown, thus decreasing the risk for infection. Moreover, Zikos
et al16 documented that the combination of CsA with low-dose MTX (10
mg/m2 on day 1; 8 mg/m2 on days 3, 6, 11) was able to reduce significantly
the risk for acute GVHD in patients with acute leukemia who received
transplants from compatible relatives.16
Dose modification of CsA was allowed when serum creatinine levels
were greater than twice the baseline value. Physicians were free to increase
the dose of CsA for patients experiencing acute GVHD. All but 5 patients
received the 4 scheduled doses of MTX.
Supportive care was standardized within each center and was uniformly
applied to patients in both groups. Usually, empirical broad-spectrum
antibiotic therapy was started when patients became febrile, and antifungal
therapy was used in the presence of either clinical evidence of fungal
infection or fever persisting after 3 days of antibiotic therapy. Patients were
given oral cotrimoxazole as prophylaxis for Pneumocystis carinii pneumo-
nia starting on the day of engraftment.
Cytomegalovirus (CMV) serologic status was studied before transplan-
tation in all patients and donors. In all patients, the expression of pp65
human CMV matrix protein was monitored to detect CMV reactivation.17
Patients experiencing reactivation of CMV infection were treated with
ganciclovir or foscarnet at a conventional dosage.
Transplant centers were free to use colony-stimulating factors to
accelerate hematopoietic recovery after BMT. Twenty of 71 patients were
given recombinant human granulocyte colony-stimulating factor (rHuG-
CSF) after transplantation. In all these patients, G-CSF was started within
the first 4 days of marrow infusion. Two more patients were given
recombinant human erythropoietin. A higher proportion of subjects given
CSA alone received rHuG-CSF than patients treated with CsA/MTX
(P 5 .06; Table 1).
Development of acute and chronic GVHD was monitored throughout
the study and graded by investigators at each participating center. Tissue
biopsy samples were obtained to confirm the diagnosis of GVHD whenever
clinically indicated and feasible. Treatment of acute and chronic GVHD
was administered according to the protocols in use at each institution.
Patient demographics and characteristics
From May 1991 to August 1998, 71 patients (45 males, 26 females) with
SAA who underwent allogeneic BMT from an HLA-identical sibling were
centrally randomized and assigned to either of the treatment arms. Patients
were treated in the centers listed in the appendix. All randomized subjects
underwent BMT and were included in the data analysis. At time of BMT,
the patients’ median age was 19 years (range, 4-46 years). Sixty-six of the
71 patients enrolled had idiopathic SAA, whereas the remaining 5 had
posthepatitis SAA (Table 1). Most patients had not received any treatment
before BMT.
HLA class I and II antigen serologic typing of donors and recipients was
performed by standard National Institutes of Health (NIH) microlymphocy-
totoxicity; low-resolution generic oligotyping was used to confirm the
DRB1 identity in most donor/recipient pairs. The median number of cells
infused was comparable in the 2 randomization arms (Table 1).
Additional details on patient and donor characteristics, pretransplant
disease history, and comparison between the 2 arms of the study are
reported in Table 1. The 2 groups were comparable for all the vari-
ables analyzed.
Definitions
Hematopoietic and lymphoid engraftment for each patient enrolled in this
study was documented at each participating center by chromosome analysis
of marrow cells and peripheral blood lymphocytes or by study of the genetic
polymorphism of variable numbers of tandem repeat short DNA sequences.
Moreover, 43 patients from 11 centers had chimeric status centrally
assessed in one of the participating centers (Dublin) on at least 3, and as
many as 15 occasions, after BMT. Assays were carried out on bone marrow
or peripheral blood slides or on cell suspensions using polymerase chain
reaction of short tandem repeats according to a previously described
method.18 These patients were part of a study on chimerism in patients with
SAA given an allograft (M.L. and S.M., unpublished data).
Myeloid and platelet engraftment were defined as the first of 3
consecutive days with an absolute neutrophil count greater than 0.5 3 109/L
and unsupported platelets greater than 50 3 109/L, respectively. Patients
were considered assessable for engraftment if they survived at least 14 days
after transplantation.
Acute and chronic GVHD were classified according to previously
published criteria.19,20 Patients with sustained donor engraftment who
survived more than 14 days and more than 3 months after transplantation
were assessable for occurrence and severity of acute and chronic GVHD,
respectively.
Overall survival time was the time between transplantation and death
from any cause. Because some surviving patients had autologous recovery
of hematopoiesis, the probability of overall survival with transfusion
independence and with complete or mixed donor chimerism was also
calculated.
Statistical analysis
Data were analyzed as of March 15, 1999. Overall survival, TRM, GVHD
occurrence, and curves for neutrophil and platelet engraftment after
transplantation (starting point) were calculated by the Kaplan–Meier
method21 and were compared using the log-rank test. Results of Kaplan-
Meier analysis were reported as probability (%) and 95% confidence
intervals (CI).
The Student t test, the Mann-Whitney U rank-sum test, and the
Kruskal-Wallis test were used to compare differences in continuous
variables between groups, and either x2 analysis or the Fisher exact test
were used to compare percentages, as appropriate. All probability values
were 2-sided, P , .05 was considered statistically significant. P . .1 was
reported as not significant (NS), whereas values between .05 and .1 were
reported in detail. The SAS package (SAS Institute, Cary, NC) was used for
analysis of the data.
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Results
The median follow-up for patients in the CsA and the CsA/MTX
groups is 50 months (range, 7-86 months) and 52 months (range,
8-94 months) for survivors (P 5 NS) and 3 months (range, 7
days-46 months) and 10 months (range, 5-17 months) for deceased
patients (P 5 NS), respectively.
Engraftment and hematopoietic recovery
All patients but 2, both in the CsA group, who died within the first 2
weeks after BMT, were evaluable for donor engraftment. Because
only one patient, in the CsA/MTX group, had primary rejection of
donor hematopoiesis, there was no difference in the engraftment
rate of patients randomized into the 2 arms (100% vs 97%,
respectively). The patient who experienced primary rejection
underwent successful retransplantation using the same donor. The
median time for neutrophil engraftment was 12 days (range, 8-45
days) and 17 days (range, 11-31 days) for patients belonging to the
CsA and CsA/MTX groups, respectively (P 5 .01). The median
time for neutrophil recovery in CsA patients who did or did not
receive G-CSF was 12 and 14 days, respectively, whereas in the
CsA/MTX group, myeloid engraftment in patients who were or
were not given G-CSF was achieved at a median of 14 and 17 days,
respectively (P 5 .06). Platelet engraftment was reached in 66 of
the 71 patients analyzed: 3 patients died before platelet recovery,
Table 1. Clinical characteristics of the patients in the 2 arms of the study
Randomization arm
PCsA CsA/MTX
No. patients 34 37
Recipient
Sex (M/F) 19/15 26/11 NS
Median age at diagnosis (years, range) 18 (4–45) 20 (6–43) NS
Median age at BMT (years, range) 18 (4–46) 20 (7–43) NS
Etiology
Idiopathic 32 (94%) 34 (92%) NS
Post hepatitis 2 (6%) 3 (8%)
Blood count at diagnosis (median value and range)
WBC (3109/L) 1.9 (0.6–4.8) 2.0 (0.2–7.0) NS
PMN (3109/L) 0.4 (0–1.2) 0.5 (0–1.3) NS
Hb (g/dL) 8.0 (3.9–10.6) 8.2 (4.2–13.0) NS
Reticulocytes (3109/L) 11 (0–19) 11 (0–30) NS
Platelets (3109/L) 15 (1–49) 11 (2–54) NS
First-line treatment
None 20 (59%) 20 (54%)
Immunosuppressive treatment 13 (38%) 14 (38%) NS
Growth factors 1 (3%) 3 (8%)
Interval diagnosis-BMT (months, median, and range) 1.6 (0.6–36) 2 (0.8–13) NS
No. of patients not transfused before BMT 0 1 NS
No. of RBC transfusions before BMT 6 (1–30) 6 (0–29) NS
No. of platelet transfusions before BMT 7 (0–97) 13 (0–133) NS
Refractoriness to PLT transfusions 11 (32%) 6 (16%)
Donor
Sex (M/F) 18/16 21/16 NS
Median age (years, range) 18 (1–40) 19 (6–50) NS
Sex match 23 (67%) 22 (59%)
Sex mismatch
Male donor/female recipient 5 (15%) 5 (14%) NS
Female donor/male recipient 6 (18%) 10 (27%)
Donor/recipient blood group compatibility
Compatibility 25 (73%) 26 (70%)
Minor incompatibility 3 (9%) 7 (19%) NS
Major incompatibility 6 (18%) 4 (11%)
HCMV serology
Negative donor/negative recipient 6 (18%) 5 (13%)
Positive donor/negative recipient 3 (9%) 8 (22%) NS
Negative donor/positive recipient 7 (20%) 8 (22%)
Positive donor/positive recipient 18 (53%) 16 (43%)
Median number of cells infused and range (3108/kg) 3.7 (1.1–10.4) 4.1 (1.4–12.5) NS
Post-BMT growth factors
None 19 (56%) 30 (81%)
EPO 1 (3%) 1 (3%) .062
G-CSF 14 (41%) 6 (16%)
Data are expressed as median and range. P values were calculated using the Mann-Whitney U rank-sum test, the Student t test, x2 analysis, or the Fisher exact test, as
appropriate.
BMT, bone marrow transplantation; WBC, white blood cell; PMN, polymorphonuclear granulocyte; RBC, red blood cell; PLT, platelet; HCMV, human cytomegalovirus; EPO,
erythropoietin; G-CSF, granulocyte–colony-stimulating factor; NS, not significant.
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one had primary rejection, and one had secondary marrow failure.
No significant difference for the kinetics of platelet recovery was
observed between the 2 groups. The median time for reaching a
self-sustained platelet count greater than 50 3 109/L was 22 days
(range, 13-127 days) and 22 days (range, 13-96) for patients in CsA
alone and the CsA/MTX group, respectively.
Five patients experienced secondary graft failure at a median of
92 days after BMT (range, 75-455 days). Three belonged to the
CsA/MTX group and 2 to the CsA group (P 5 NS). Four of these 5
patients are alive and transfusion independent. One received a
second allograft from the same donor, which resulted in a complete
donor chimerism.
Graft versus host disease
Grade 2 to 4 acute GVHD developed in 23 (33%) of the 69
evaluable patients. The cumulative probability of developing grade
2 to grade 4 acute GVHD was 38% (21–54) and 30% (15–44) for
patients in the CsA and the CSA/MTX group, respectively
(P 5 NS) (Figure 1). No patients in either treatment group
experienced grade 4 acute GVHD. Acute GVHD developed in
patients who were randomized to the CsA or the CsA/MTX arms at
a median of 13 (range, 6-62 days) and 23 (range, 9-45 days) after
transplantation, respectively (P 5 .07). Table 2 shows the details of
organ involvement by acute GVHD. The differences between the 2
arms were not statistically significant.
Chronic GVHD developed in 23 of the 66 (35%) assessable
patients. In all patients, chronic GVHD followed acute GVHD, and
no case of de novo disease was observed. Nine patients had
progressive chronic GVHD, whereas in the remaining 14 the
disease developed after a period of quiescence, with no difference
between the 2 randomization arms. Seventeen patients, 6 in the
CsA group and 11 in the CsA/MTX group, had limited skin chronic
GVHD, and 6 patients—3 in the CsA group and 3 in the CsA/MTX
group—had the extensive form of the disease. The Kaplan-Meier
estimate of chronic GVHD occurrence was 30% (13–46) for the
CsA group and 44% (26–62) for the CsA/MTX group (P 5 NS;
Figure 1). Chronic GVHD developed in patients randomized to the
CsA and the CsA/MTX groups at a median of 3.5 months (range,
3-13 months) and 4 months (range, 3-37 months) after BMT,
respectively (P 5 NS). When CsA tapering was started it did not
have any influence on the development of chronic GVHD. Median
Karnofsky score of surviving patients with chronic GVHD was
100% (50–100), with no difference between the 2 randomization
arms. One patient in the CsA arm died of chronic GVHD.
Transplantation-related death
Nine patients died a median of 5 months after transplantation
(range, 7 days-48 months). Seven patients were in the CsA group
and the remaining 2 were in the CsA/MTX group. Details on the
causes of death are reported in Table 3. Infectious complications
accounted for 5 of the deaths observed in the study population. One
child randomized to the CsA arm died of acute myeloid leukemia in
the donor cells 15 months after transplantation. Grades 2 and 3
GVHD had been diagnosed in 6 of 7 patients evaluable for GVHD
and who died.
The 100-day TRM probability was comparable in the 2
randomization arms (Table 4). The 1-year TRM probability was 9%
(2–18) for the entire study population, whereas it was 15% (3–27)
and 3% (0–15) for the CsA and the CsA/MTX group, respectively
Table 2. GVHD incidence in the 2 randomization arms
Randomization arm
PCsA CsA/MTX
Acute GVHD
(69 evaluable patients)
No. of patients 32 37
Absent 13 (41%) 17 (46%)
Grade 1 7 (22%) 9 (24%)
Grade 2 12 (37%) 10 (27%) NS
Grade 3 0 (0%) 1 (3%)
Grade 4 0 (0%) 0 (%)
Organ involvement in acute GVHD
(39 patients)
No. of patients 19 20
Skin 8 (42%) 9 (45%) NS
Liver 1 (5%) 0 (0%) NS
Skin 1 intestine 6 (32%) 8 (40%) NS
Skin 1 liver 4 (21%) 2 (10%) NS
Skin 1 intestine 1 liver 0 (0%) 1 (5%) NS
Chronic GVHD
(66 evaluable patients)
No. of patients 31 35
Absent 22 (71%) 21 (60%)
Limited 6 (19%) 11 (31%) NS
Extensive 3 (10%) 3 (9%)
Figure 1. Development of GVHD. Cumulative probability of grade 2 to 4 acute (top)
and chronic (bottom) GVHD for the CsA group (dotted line) and the CsA/MTX group
(continuous line) is shown. N, number of patients in each arm of randomization; EV,
number of events occurring in each arm of randomization.
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(P 5 .07). Because 2 more patients died beyond 1 year after BMT
as a result of chronic GVHD and viral encephalitis (Table 4),
ultimately the 5-year probability of dying was 6% (0–15) and 19%
(5–34) for patients in the CsA/MTX or the CsA alone group,
respectively (P 5 .09).
Survival, survival with transfusion independence, and
complete or mixed donor chimerism
Sixty-two of the 71 enrolled patients (87%) are alive. The 5-year
Kaplan-Meier estimate of survival is 86% (78–95) for the entire
cohort of patients studied, whereas it is 94% (87–100) for patients
in the CsA/MTX group, a value significantly better than the 78%
(63–93) estimate for patients randomized in the CsA group
(P 5 .05) (Figure 2).
Fifty-nine patients (83%) are alive and transfusion independent
and have complete or mixed donor chimerism. Of these, 2 patients
in the CsA/MTX group achieved donor chimerism after a second
allograft from the same donor. The 5-year Kaplan-Meier estimates
of survival, with transfusion independence and mixed or complete
donor chimerism, are comparable in the 2 randomization groups
and are shown in Figure 3. Details on donor chimerism according
to the randomization arm are reported in Table 4. Three more
patients, one in the CsA group and 2 in the CsA/MTX group, are
alive and transfusion independent with autologous recovery of
hematopoiesis (Table 4). Overall survival was 98% (94–100) and
70% (50–91) for evaluable subjects without or with grade 1 acute
GVHD and for those with grade 2 or 3 acute GVHD, respectively
(P , .005; Figure 4).
The cumulative probability of survival for patients younger or
older than 18 years was 91% (80–100) and 83% (70–96), respec-
tively (P 5 NS). The advantage in terms of survival offered by
Table 4. Detailed outcome of the patients enrolled
Total
(71 patients)
Randomization arm
P
CsA
(34 patients)
CsA/MTX
(37 patients)
Engraftment:
Engraftment 68 (99%) 32 (100%) 36 (97%)
Rejection 1 (1%) 0 (0%) 1 (3%) NS
Not evaluable 2 2 0
Late marrow failure 5 (7%) 2 (6%) 3 (8%) NS
Autologous reconstitution 5 (7%) 2 (6%) 3 (8%) NS
Chimerism:
Donor 54 (76%) 26 (76%) 28 (76%)
Mixed 9 (13%) 4 (12%) 5 (13%) NS
Recipient* 6 (8%) 2 (6%) 4 (11%)
Not evaluable 2 (3%) 2 (6%) 0 (0%)
Patients who achieved transfusion independence:
With donor chimerism after 1st BMT 61 (86%) 29 (85%) 32 (86%)
With donor chimerism after 2nd BMT 2 (3%) 0 (0%) 2 (5%) NS
With autologous reconstitution 3 (4%) 1 (3%) 2 (5%)
Total 66 (93%) 30 (88%) 36 (97%)
Transplant-related death:
Within 100 days 2 (3%) 2 (6%) 0 (0%)
Within 1 year after BMT 6 (8%) 5 (15%) 1 (3%) NS
Total 8 (11%) 6 (18%) 2 (5%)
Patients alive 62 (87%) 27 (79%) 35 (95%) .058
Patients alive, transfusion independent and with
donor engraftment:
After 1st BMT 57 (80%) 26 (76%) 31 (84%)
After 2nd BMT 2 (3%) 0 (0%) 2 (5%) NS
Total 59 (83%) 26 (76%) 33 (89%)
*Two patients in the CsA/MTX group achieved complete donor chimerism after a second BMT from the same donor of the first transplant.
Table 3. Causes of death in the 2 groups
Randomization arm
CsA CsA/MTX
Transplantation-related causes
Chronic GVHD 1
Viral infections 2 1
Fungal infections 1 1
Organ failure 2
Secondary leukemia 1
Total 7 2
Figure 2. Probability of survival. Cumulative probability of survival for the CsA
group (dotted line) and the CsA/MTX group (continuous line) is shown. N, number of
patients in each arm of randomization; EV, number of events occurring in each arm of
randomization.
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adding MTX to GVHD prophylaxis was comparable in children and
adults (data not shown). Overall survival of patients who did or did not
receive G-CSF was 89% (75–100) and 85% (75–95), respectively
(P 5 NS). None of the other factors possibly influencing outcomes
for patients with SAA after BMT—including absolute neutrophil
count and platelet count at diagnosis, number of pre-BMT transfu-
sions, refractoriness to platelet transfusion, prior treatment, number
of cells infused, and interval between diagnosis and BMT—was
associated with an increased risk for treatment failure (data
not shown).
Discussion
This randomized, multicenter study documents that the combina-
tion of CsA and short-term MTX for GVHD prevention offers a
survival advantage in comparison to CsA alone in patients with
acquired SAA who receive an allograft from an HLA-identical
sibling. Our data differ from those reported in a retrospective study
from the International Bone Marrow Transplant Registry (IB-
MTR),6 which failed to demonstrate a significant improvement in
survival rate by adding MTX to CsA. In contrast, our data confirm
previously published reports showing a beneficial effect of the
combination of CsA/MTX for GVHD prophylaxis on SAA patient
survival, mainly because of acute GVHD prevention.9-11 In our
population the combination of CsA and MTX did not affect the
incidence of acute or chronic GVHD; hence, the advantage offered
by adding MTX seems to be related to other factors, such as lower
risk for infectious complications or organ toxicity. The later develop-
ment (ie, in a phase of better immune competence) of acute GVHD,
observed in patients given CsA and MTX, may have favorably
influenced the mortality rate, reducing the risk for life-threatening
infections. However, other unknown factors might have been at work to
improve the survival rate of patients given the combination treatment.
The advantage in terms of survival offered by adding short-term
MTX is lost when stable engraftment of donor hematopoiesis and
transfusion independence are assessed. The Kaplan-Meier estimates of
survival with transfusion-independence and complete or mixed donor
chimerism were comparable in the 2 randomization arms.
The incidence of either primary or late graft failure in our cohort was
8%. This value is comparable to or better than those previously reported
by retrospective studies of the IBMTR6,8 and slightly higher than the 5%
documented by Storb et al,7 who added antithymocyte globulin to
cyclophosphamide during the preparative regimen.
Nine of the 63 surviving patients with stable engraftment of
donor hematopoiesis were mixed chimeras (Table 1). This confirms
that mixed chimerism is relatively frequent among patients who
undergo transplantation for aplastic anemia and that it is not
uniformly associated with graft failure.22 Similar results are seen in
patients with thalassemia given BMT from a compatible sibling.23
Three patients survive with autologous hematopoietic recovery
and transfusion independence. This finding is in agreement with
previously published results, documenting the efficacy of high-
dose cyclophosphamide without BMT in restoring normal hemato-
poiesis,24-26 and it provides further support to the hypothesis that
SAA is a disorder in which damage to hematopoietic stem cells may
lead to an autoimmune response directed against the bone marrow.5,27
The earlier neutrophil recovery documented in our patients
given CsA alone can be attributed both to the detrimental effect of
MTX on the kinetics of myeloid recovery12 and to the higher
percentage of patients treated with hematopoietic growth factors,
which have been shown to accelerate neutrophil reconstitution
in allogeneic BMT recipients.28,29 However, the delay in neutrophil
recovery for our patients given CsA/MTX was not accompanied by
an increased risk for either fungal or bacterial infections. Moreover,
we have been unable to document any detrimental effect played by
MTX on platelet recovery, confirming the results previously
published by Storb et al12 in a randomized trial comparing
CsA/MTX to CsA alone in patients with acute leukemia.
As mentioned above, patients receiving combination treatment
did not show a lower probability for acute or chronic GVHD.
However, it must be noted that the incidence of severe acute GVHD
was particularly low in the overall population. No patient had grade
4 GVHD, and only one patient in the CsA/MTX group had grade 3
acute GVHD. This low incidence and severity of GVHD might be
attributed to the young age of our population. In fact, approxi-
mately half the patients were children, and previously published
studies have reported a low incidence of GVHD in pediatric
patients given transplants from compatible siblings.11,30 We cannot
exclude that the large number of centers involved in this study and the
relatively low number of patients who underwent transplantation in each
center might have led to an underestimation of the real incidence of
Figure 4. Probability of survival according to the development of acute GVHD.
Cumulative probability of survival for patients without or with grade 1 acute GVHD
(continuous line) and for patients with grade 2 or 3 acute GVHD (dotted line) is shown.
N, number of patients in each arm of randomization; EV, number of events occurring
in each arm of randomization.
Figure 3. Probability of survival with transfusion independence and mixed/
complete donor chimerism. Cumulative probability of survival with transfusion
independence and mixed/complete donor chimerism for the CsA group (dotted line)
and the CsA/MTX group (continuous line) is shown. N, number of patients in each
arm of randomization; EV, number of events occurring in each arm of randomization.
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GVHD. The persistence of residual host cells and the low-intensity
preparative regimen used might have also contributed to a decrease in
the probability of GVHD.Animal models have demonstrated that mixed
chimerism is associated with reduced susceptibility to GVHD, probably
through mechanisms of central tolerance with negative selection of
host-reactive and donor-reactive T cells.31,32 A reduced incidence of
acute GVHD associated with mixed chimerism was also reported in
patients with SAA receiving BMT from compatible relatives.33 More-
over, it has been hypothesized that the cytokine storm, secondary to the
intensity of the conditioning regimen and its related tissue damage,
triggers the development of GVHD.34
Despite the negligible incidence of severe acute GVHD in our
study population, our data confirm the previously reported9,35,36
detrimental effect played by grade 2 to 4 acute GVHD on the
outcome of patients with SAA given an allograft. The survival
probability rates of patients with grade 0 to 1 and grade 2 to 4 acute
GVHD were 98% and 70%, respectively (P , .005). This finding
supports the concept that the most effective pharmacologic strate-
gies for GVHD prevention should be used in patients with SAA
given unmanipulated BMT.
We conclude that the combination of CsA and short-term MTX
for GVHD prevention improves the probability for survival in
patients with SAA given allogeneic BMT from compatible siblings.
Whether this advantage, in terms of overall survival, results in
better survival with transfusion independence and mixed or com-
plete donor chimerism remains to be demonstrated.
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